The Pfizer/ASA/Columbia University Symposium on Risks and Opportunities of AI in Clinical Drug Development will be held May 18 from 8:30 a.m. to 4:30 p.m. at the Columbia University School of Social Work. The event is jointly sponsored by Pfizer Inc., the American Statistical Association, and the Statistics Department and Data Science Institute at Columbia University.
Our world increasingly relies on data and computing to create knowledge, make critical decisions, and better predict the future. Data science has emerged to support these data-driven activities by integrating and developing ideas, concepts, and tools from computer science, engineering, information science, statistics, and domain fields. Data science now drives fields as diverse as biology, astronomy, material science, political science, and medicine—not to mention vast tracts of the global economy, key government activities, and quotidian social and societal functions.
The pharmaceutical enterprise has been slower to respond, especially to the rapid developments in AI, but tectonic shifts are underway in approaches to the discovery, development, evaluation, registration, monitoring, and marketing of medicines for the benefit of patients and the health of the community.
The purpose of this symposium is to provide a forum for experts from various stakeholders—including the pharmaceutical industry, regulatory agencies, and academia—with the aim of advancing the use of artificial intelligence (AI) in drug development and deployment.
While there is much discussion about the potential of AI and modern machine learning tools to transform the drug development paradigm, there is a growing recognition of the paucity of research about the inevitable pitfalls and unintended consequences of the digital revolution in this area of application. As we move toward personalized and truly evidence-based medicine, the use of AI and machine learning to optimize drug deployment raises a whole different set of challenges.
This forum is, therefore, expected to serve as a platform for distinguished statisticians, data scientists, regulators, and other professionals to address the challenges and opportunities of AI in pharmaceutical medicine; to foster collaboration among industry, academia, regulatory agencies, and professional associations; and to propose recommendations with policy implications for proper implementation of AI in promoting public health.
Leave a Reply